<DOC>
	<DOCNO>NCT00117884</DOCNO>
	<brief_summary>The purpose study evaluate efficacy 851B gel range concentration dose regimen high-risk cervical human papillomavirus infection woman .</brief_summary>
	<brief_title>Efficacy 851B Gel Treating High-Risk Cervical Human Papillomavirus Infection Women .</brief_title>
	<detailed_description>Cervical cancer cause infection specific genotype human papillomavirus refer oncogenic high-risk human papillomavirus . Current epidemiologic evidence suggest 80 % sexually active woman become infected lifetime human papillomavirus 50 % infection due high-risk human papillomavirus . With US annual rate cervical cancer range 13,000/year , substantial number woman leave uncertainty regard whether infection clear spontaneously progress cancer . Subjects participate study require visit clinic approximately 15 16 visit , maintain diary self-dosing menstruation cycle . The total time participation study approximately 27 month .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Papillomavirus Infections</mesh_term>
	<criteria>Willing acceptable method birth control Have Pap smear result LSIL ASCUS Is high risk HPV positive No evidence highgrade disease glandular abnormality , Complete visualization lesion margin transformation zone , No uncontrolled significant medical illness sexually transmitted infection , Taking restricted medication interferon , immunomodulators , cytotoxic drug , investigational drug , steroid .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Papillomavirus infection ;</keyword>
	<keyword>Cervix Dysplasia</keyword>
</DOC>